Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the vaccine components to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pegu, Poonam, Vaccari, Monica, Gordon, Shari, Keele, Brandon F., Doster, Melvin, Guan, Yongjun, Ferrari, Guido, Pal, Ranajit, Ferrari, Maria Grazia, Whitney, Stephen, Hudacik, Lauren, Billings, Erik, Rao, Mangala, Montefiori, David, Tomaras, Georgia, Alam, S. Munir, Fenizia, Claudio, Lifson, Jeffrey D., Stablein, Donald, Tartaglia, Jim, Michael, Nelson, Kim, Jerome, Venzon, David, Franchini, Genoveffa
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2013
Assuntos:
Vaccines and Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554145/
https://ncbi.nlm.nih.gov/pubmed/23175374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02544-12
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares